ArticleAdvances in therapy2026
Using Pre-Study Patient Interviews to Refine Electronic Patient-Reported Outcomes in Clinical Research of Ustekinumab Induction for Ulcerative Colitis (SIRIUS Study).
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04963725 (Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice, Measured Using Patient-Reported Outcomes), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice, Measured Using Patient-Reported Outcomes
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDaily electronic patient-reported outcome (ePRO) collection enables assessment of symptom fluctuations in ulcerative colitis (UC); however, high-frequency data entry can impose operational and psychological burdens that may affect data quality and feasibility. Incorporating patient perspectives during study preparation may help mitigate these challenges. Structured pre-study patient interviews were conducted to inform potential refinements to ePRO questionnaire design and operational procedures in the SIRIUS study, a prospective observational study in Japanese patients with UC, and to explore their potential impact on study feasibility, including retention and ePRO completion.
methodsBefore initiating the SIRIUS study, pre-study patient interviews were conducted by an operationally independent external organization. The pre-study interviews assessed the usability and acceptability of the planned ePRO application and materials. Patient feedback was thematically analyzed to inform potential refinements to questionnaire wording, manuals, onboarding support, troubleshooting procedures, and compensation. These refinements were considered for inclusion in the SIRIUS study.
resultsTwenty-six adults with UC participated in interviews. Patient input identified key usability and burden-related issues and led to several modifications: questionnaire items were revised to reduce the burden associated with recalling pre-onset bowel habits for stool frequency, and the overall condition scale was adjusted to allow for both improvement and worsening. Manuals were simplified and tailored to varying levels of technological literacy, onboarding included in-person support, and a dedicated troubleshooting hotline was established. Compensation was set at an appropriate level. A total of 135/136 enrolled patients (99.3%) completed the ustekinumab induction period in the SIRIUS study, and the daily ePRO completion rate was 94.2%.
conclusionsStructured patient input prior to study initiation identified modifiable barriers to high-frequency ePRO collection and informed concrete refinements to study design and operations. While causality cannot be inferred from this uncontrolled case study, high retention and ePRO completion rates were observed, suggesting that patient-informed refinements may have supported participant understanding and adherence.
trial registrationClinicalTrials.gov identifier NCT04963725 (registered July 8, 2021). https://clinicaltrials.gov/study/NCT04963725?cond=Ulcerative%20Colitis&term=daily&intr=Ustekinumab&rank=2.
Indexed as
Identifiers
42766096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.